IMNM
Immunome, Inc.
$21.66
-1.30
(-5.66%)
Mkt Cap
2.07B
Volume
1,027,175
52W Range
7.96-27.65
Sector
Healthcare
Beta
2.12
EPS (TTM)
-2.39
P/E Ratio
-8.83
Revenue (TTM)
4.01M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.94M | 9.04M | 14.02M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (212.39M) | (292.96M) | (106.81M) | (36.90M) | (24.71M) | (17.84M) | (10.55M) | (7.84M) |
| EPS | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -1.69 | -1.84 | -7.18 |
| Free Cash Flow | (200.60M) | (164.30M) | (8.40M) | (28.94M) | (18.30M) | (12.72M) | (9.83M) | (7.63M) |
| FCF / Share | -2.30 | -2.80 | -0.42 | -2.39 | -1.59 | -1.26 | -1.71 | -6.99 |
| Operating CF | (190.92M) | (110.79M) | (7.57M) | (28.69M) | (18.23M) | (12.13M) | (9.60M) | (7.41M) |
| Total Assets | 683.19M | 240.24M | 148.54M | 24.05M | 57.92M | 44.52M | 5.06M | 4.45M |
| Total Debt | 3.85M | 4.83M | 1.65M | 291,000 | 317,000 | 613,000 | 564,000 | 1.18M |
| Cash & Equiv | 653.48M | 143.35M | 98.68M | 20.32M | 49.23M | 39.77M | 2.54M | 1.60M |
| Book Value | 634.34M | 181.16M | 119.88M | 16.65M | 48.19M | 41.34M | (35.63M) | (25.20M) |
| Return on Equity | -0.33 | -1.62 | -0.89 | -2.22 | -0.51 | -0.43 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 4.01M | 2.93M | 2.74M | 2.91M | 2.36M | 1.03M | 3.83M | 3.56M | 4.26M |
| Net Income | (53.84M) | (69.90M) | (57.46M) | (43.40M) | (41.64M) | (80.25M) | (47.10M) | (36.12M) | (129.49M) | (92.63M) | (4.34M) | (5.56M) |
| EPS | -0.48 | -0.76 | -0.65 | -0.50 | -0.52 | -1.28 | -0.78 | -0.60 | -12.56 | -4.22 | -0.36 | -0.46 |
| Free Cash Flow | (61.64M) | (51.95M) | (41.63M) | (50.31M) | (56.72M) | (43.44M) | (35.71M) | (25.74M) | (13.33M) | (17.81M) | (8.65M) | (6.01M) |
| FCF / Share | -0.54 | -0.59 | -0.47 | -0.58 | -0.71 | -0.69 | -0.59 | -0.43 | -1.29 | -0.81 | -0.71 | -0.49 |
| Operating CF | (58.64M) | (47.95M) | (40.51M) | (49.40M) | (53.05M) | (42.06M) | (34.17M) | (23.40M) | (11.17M) | (17.46M) | (8.61M) | (5.67M) |
| Total Assets | 619.79M | 683.19M | 299.38M | 296.29M | 342.69M | 240.24M | 256.90M | 296.21M | 319.75M | 148.54M | 93.16M | 41.44M |
| Total Debt | 3.69M | 3.85M | 4.01M | 4.14M | 4.77M | 4.83M | 2.72M | 2.77M | 1.62M | 1.65M | 371,000 | 489,000 |
| Cash & Equiv | 582.69M | 653.48M | 272.64M | 143.88M | 257.61M | 143.35M | 155.57M | 165.33M | 269.72M | 98.68M | 90.64M | 38.42M |
| Book Value | 588.69M | 634.34M | 263.92M | 269.27M | 307.13M | 181.16M | 214.91M | 253.84M | 285.57M | 119.88M | 6.08M | 9.34M |
| Return on Equity | -0.09 | -0.11 | -0.22 | -0.16 | -0.14 | -0.44 | -0.22 | -0.14 | -0.45 | -0.77 | -0.72 | -0.60 |
IMNM News
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead
Max Rosett Sells 65,000 Shares of Immunome (NASDAQ:IMNM) Stock
Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome (IMNM) Moves 13.3% Higher: Will This Strength Last?
Immunome: Upcoming NDA, Valuation, And Investment Case